AriBio’s oral drug candidate, AR1001, slowed cognitive decline by 31% in a subgroup of early-stage Alzheimer’s patients who were not taking other standard treatments during a global Phase 3 trial.
The results from the Polaris-AD trial, which involved 1,535 participants, showed that the drug—a phosphodiesterase-5 (PDE5) inhibitor originally developed for erectile dysfunction—met its primary endpoint only within this specific monotherapy cohort. According to Fierce Pharma, patients in the monotherapy group receiving AR1001 showed a 1.16-point advantage over the placebo group on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13.
Mixed Results in the Full Trial Population
While the findings in the monotherapy group were positive, the study did not demonstrate a statistically significant benefit when researchers analyzed the entire group of 1,535 patients, which included individuals already taking common Alzheimer’s medications like acetylcholinesterase inhibitors or memantine, The Telegraph reported. The trial measured decline using an 18-point scale covering memory, judgment, and everyday abilities.
"The trial demonstrated a statistically significant slowing of clinical decline in participants who were not taking other commonly used Alzheimer’s medications alongside the trial drug," Dr. Scales remarked, as reported by The Telegraph.

Biomarker Data and Safety Profile
The trial results provided a nuanced picture of the drug’s impact on biological markers associated with Alzheimer’s. Data showed that cerebrospinal fluid (CSF) p-tau217 levels numerically favored AR1001, but there was no observable difference in the CSF Aβ42/40 ratio, which is used to evaluate the presence of amyloid plaque, according to Fierce Pharma.
Regarding safety, the trial reported that deaths occurred in 0.5% of the AR1001 group and 0.3% of the placebo group. Discontinuation of the study drug due to adverse events was 5.2% for those receiving AR1001 and 1.7% for the placebo group.
"The CDR-SB finding in the prespecified monotherapy population and the safety profile are encouraging. Further analysis of the biomarker data and secondary endpoints, in conjunction with the results from the total patient population, is necessary to determine the therapeutic impact of AR1001 for early Alzheimer’s disease," stated Sharon Sha, M.D., of Stanford University and principal investigator of the trial, in comments provided to Fierce Pharma.

Next Steps for AriBio and Fosun Pharma
The South Korean company AriBio is now preparing to discuss these findings with U.S. regulators to determine the potential path for approval. Meanwhile, the Chinese firm Fosun Pharma holds an option to in-license AR1001 for markets in the U.S., Europe, and Japan.
Under the terms of a $60 million deal signed in May, Fosun has 90 days after receiving the full dataset to decide whether to exercise that option, a move that would trigger up to $180 million in additional payments, Fierce Pharma noted.
Comparing AR1001 with Viagra
Is AR1001 the same as Viagra?
AR1001 is a PDE5 inhibitor, the same class of medication as Viagra, but it is being developed specifically for Alzheimer’s disease. The Independent noted that while they share a drug class, people should not attempt to use Viagra to treat Alzheimer’s.
What are the primary differences between this drug and existing treatments?
Unlike other disease-modifying treatments that have shown benefit in late-stage trials, AR1001 is a once-daily oral tablet. The Independent reported that this delivery method could simplify treatment for patients if the drug receives regulatory approval.
Further evaluation of the full dataset is currently underway. "We look forward to seeing the full results from this trial and how this drug progresses," said Dr. Richard Oakley, associate director for research and innovation at the Alzheimer’s Society, to The Independent.